BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/19/2022 3:18:56 AM | Browse: 295 | Download: 544
 |
Received |
|
2021-11-11 12:55 |
|
Peer-Review Started |
|
2021-11-11 12:57 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-27 02:50 |
|
Revised |
|
2021-12-29 11:00 |
|
Second Decision |
|
2022-03-10 05:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-03-17 04:18 |
|
Articles in Press |
|
2022-03-17 04:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-03-08 01:17 |
|
Typeset the Manuscript |
|
2022-04-11 09:31 |
|
Publish the Manuscript Online |
|
2022-04-19 03:18 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Angeliki Bourazana, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis and Andrew Xanthopoulos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andrew Xanthopoulos, FACC, MD, PhD, Doctor, Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com |
| Key Words |
Dipeptidyl peptidase-4 inhibitors; Diabetes mellitus; Outcomes; Meta-analysis; Heart failure; Atrial flutter |
| Core Tip |
Dipeptidyl peptidase-4 inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 diabetes mellitus. However, their effect on cardiovascular outcomes in diabetic patients has been neutral. The potential correlation between atrial flutter and dipeptidyl peptidase-4 inhibitors administration is an interesting finding, but since currently there is no sheer underlying pathophysiologic mechanism to justify it, more evidence is required. |
| Publish Date |
2022-04-19 03:18 |
| Citation |
Bourazana A, Giamouzis G, Skoularigis J, Triposkiadis F, Xanthopoulos A. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World J Cardiol 2022; 14(4): 266-270 |
| URL |
https://www.wjgnet.com/1949-8462/full/v14/i4/266.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v14.i4.266 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
